Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/L23-0410 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.
Diabetologia
July 2025
Internal Medicine Department, Endocrine Division (SEMPR), Universidade Federal do Parana, Curitiba, Brazil.
Comparison of marine algae-based rumen buffer with sodium bicarbonate buffer and its role in increasing milk value.
J Dairy Res
November 2024
Research, Teaching and Extension Center in Livestock (NUPEEC), Federal University of Pelotas (UFPel), 96160-000, Pelotas, Brazil.
This study aimed to evaluate the effect of marine-based rumen buffer () supplementation on rumen health as well as milk yield and composition and also behavioural and metabolic parameters of dairy cows. Thirty-six lactating multiparous Holstein cows were used with a milk yield average of 39 kg/d and 64 d in milk. The experiment was conducted over 60 d using two groups: control (CON; = 18) was supplemented with sodium bicarbonate at 1.
View Article and Find Full Text PDFA phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors.
ESMO Open
March 2025
Early Drug Development Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
Background: KO-947, a potent, intravenously administered, extracellular signal-regulated kinase (ERK) inhibitor, has demonstrated activity in preclinical models. This phase I trial of KO-947 evaluated maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with relapsed/refractory solid tumors.
Materials And Methods: This multicenter, open-label, dose-escalation study evaluated KO-947 0.
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.
Clin Cancer Res
February 2025
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Purpose: FHD-609, a potent, selective, heterobifunctional degrader of bromodomain-containing protein 9 (BRD9), was evaluated for treating patients with advanced synovial sarcoma or SMARCB1-deficient tumors.
Patients And Methods: In this multinational, open-label, phase I study (NCT04965753), patients received FHD-609 intravenously at escalating doses either twice weekly (5-80 mg; n = 40) or once weekly (40-120 mg; n = 15).
Results: Fifty-five patients received FHD-609 for a median of 43 days.